“I’m very excited to join an institution like NYU Langone that embraces such a strong patient-centered model of treatment while emphasizing the importance of clinical trials and translational research” says Dr. Evans.

About Dr. Sulman
After receiving his medical degree and postgraduate doctoral degree at Temple University School of Medicine, Dr. Sulman completed an internship at Albert Einstein Medical Center in Philadelphia and a residency and research fellowship at The University of Texas MD Anderson Cancer Center, the latter as part of the highly-selective Holman Pathway in radiation oncology.
Dr. Sulman is a nationally recognized figure in brain tumor research, as evidenced by his selection to multiple prestigious committees, including his recent election to the Board of the Society for Neuro-Oncology. He has authored more than 100 manuscripts, including publications in top-tier peer-reviewed journals, such as Nature, Cancer Cell, Neuro-Oncology, and Clinical Cancer Research.

Dr. Sulman also has been recognized for his many achievements—he received the American Society for Radiation Oncology Translational Research in Radiation Oncology and Radiology Symposium Travel Award in 2007 and 2008, and the American Association for Cancer Research Scholar-in-Training Award in 2007. He serves as principal investigator on R01 grants and Specialized Programs of Research Excellence projects funded by the NIH and directs integral biomarker evaluation on some of the largest, NIH-funded clinical trials for brain tumor patients.

“Interacting with patients is a special part of my job, so to join an institution like Perlmutter Cancer Center that not only places unmatched value on comprehensive patient care, but also supports collaborative and translational research, is particularly exciting,” says Dr. Sulman.

Back to HCB News

Rad Oncology Homepage